Recruiting

Treating Diabetic Foot Ulcers, Comparing Two Topical Antimicrobial Agents, Dakin´s and Prontosan

202 Diabetic foot ulcers will be cleaned with either Hypochlorous Acid, HClO or Polyhexamethylene biguanide, PHMB twice a week until healed or 24 weeks. Primary objective is to find out if cleaning DFU with HClO is more effective in obtaining complete healing than PHMB.

I'm interested View official listing
ClinicalTrials.gov IDNCT05132179
PhaseNA
Enrollment202
SponsorVastra Gotaland Region
Age18 Years – 100 Years
SexALL
I'm interested View official listing

Conditions studied

Diabetic Foot Ulcer

About this study

202 Diabetic foot ulcers will be cleaned with either Hypochlorous Acid, HClO or Polyhexamethylene biguanide, PHMB twice a week until healed or 24 weeks. Primary objective is to find out if cleaning DFU with HClO is more effective in obtaining complete healing than PHMB.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: Informed consent obtained before trial-related activities, * Diabetes Mellitus type 1 or 2 or due to pancreatitis * Foot ulcer since 3 weeks or more * Ulcer surface area 9 mm2 or more * Age 18 years old or more Exclusion Criteria: * Persons in need of intensive care or dialysis * Persons in need of vascular intervention, critically impaired circulation (toe-pressure \< 30 mm Hg) * Event of myocardial infarction or stroke during the last three months * Debut of atrial fibrillation or heart failure during the last three months * Current treatment of malignancy * Treatment with corticosteroids with a dose corresponding to 50 mg Prednisolon * Severe wound infection according to International Working Group of Diabetic Foot, IWGDF at least two of following signs: body temperature \<36 C or \>38 C, heart rate \>90/minute, respiration rate \>20/minute, LPK \>12x10\^9/L * Planned changed residence in the coming 12 months requiring change of clinic for wound treatment during the follow-up time * Age under 18 years old * Diabetes of MOODY type * Current known pregnancy or planned pregnancy next 26 weeks * Participation in another clinical trial evaluating any treatment * Other reasons judged by the investigator that the patient is unsuitable for participation in the study

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.